Trial Profile

A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Sep 2024 According to an Immuron media release, clinical trial data on IMM-529 provides support for continued development of IMM-529.
02 Jul 2024 According to an Immuron media release, the company has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529.
30 Jun 2023 According to an Immuron Media Release, In the next twelve months the Company anticipates FDA submission of an IND for IMM-529 for Clostridioides difficile (CDI).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com